Jim Simons Viridian Therapeutics, Inc.\De Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Renaissance Technologies LLC holds 59,600 shares of VRDN stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,600

Previous 247,600 75.93%

Holding current value

$1.2 Million

Previous $3.22 Million 57.93%

% of portfolio

0.0%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$12.16 - $23.33 $2.29 Million - $4.39 Million	-188,000 Reduced 75.93%	59,600 $1.36 Million
Q2 2024 Aug 09, 2024	SELL	$11.6 - $17.26 $163,560 - $243,366	-14,100 Reduced 5.39%	247,600 $3.22 Million
Q1 2024 May 13, 2024	BUY	$17.09 - $23.82 $4.24 Million - $5.91 Million	248,300 Added 1852.99%	261,700 $4.58 Million
Q4 2023 Feb 13, 2024	SELL	$11.12 - $22.5 $576,016 - $1.17 Million	-51,800 Reduced 79.45%	13,400 $292,000
Q3 2023 Nov 14, 2023	SELL	$15.16 - $24.7 $163,728 - $266,760	-10,800 Reduced 14.21%	65,200 $1 Million
Q2 2023 Aug 11, 2023	BUY	$22.57 - $29.67 $907,314 - $1.19 Million	40,200 Added 112.29%	76,000 $1.81 Million
Q1 2023 May 12, 2023	BUY	$25.04 - $37.6 $896,432 - $1.35 Million	35,800 New	35,800 $911,000
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $1.09 Million - $2.59 Million	101,600 New	101,600 $2.08 Million
Q2 2021 Aug 13, 2021	SELL	$14.34 - $18.67 $189,861 - $247,190	-13,240 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$15.5 - $24.93 $205,220 - $330,073	13,240 New	13,240 $221,000

Others Institutions Holding VRDN

# of Institutions

179

Shares Held

76.8M

Call Options Held

581K

Put Options Held

439K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $806M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account